New Obesity Drug Retatrutide: 25% Weight Loss, Now Published in NEJM
Retatrutide has been one of the most talked-about next-generation obesity drugs. Now the phase 3 results are no longer just conference buzz or topline announcements — they have been formally published in the New England Journal of Medicine.
This matters because publication gives us the full paper: the actual trial design, the side-effect profile, and the limits of what this drug can and cannot yet claim.
What the trial found
1. The weight-loss effect was striking. In this phase 3, randomized, double-blind trial, the mean percent change in body weight at 80 weeks was −17.6% with 4 mg, −23.7% with 9 mg, and −25.0% with 12 mg, compared with −3.9% with placebo.
2. The study was large. A total of 2,339 adults with obesity and without diabetes underwent randomization. That makes this a much more important dataset than the earlier phase 2 signal.
3. Two important obesity complications improved. In the prespecified subgroup with knee osteoarthritis (574 participants), pain scores improved more with retatrutide than with placebo. In the subgroup with obstructive sleep apnea (243 participants), apnea–hypopnea events per hour also fell substantially more with retatrutide.
4. Side effects were common, especially gastrointestinal ones. Nausea, diarrhea, constipation and vomiting were frequent, particularly during dose escalation. At the 12-mg dose, 11.2% stopped treatment because of adverse events, compared with 4.6% on placebo.
What this paper does not tell us
It does not tell us whether retatrutide is better than tirzepatide or semaglutide. There was no active-comparator arm. So comparing the 25% result here with numbers from separate semaglutide or tirzepatide trials is interesting, but it is not a head-to-head comparison.
It does not settle long-term safety. The trial was not designed to answer rare-event safety questions such as pancreatitis or cardiovascular outcomes. Those questions need larger and longer studies.
It does not tell us what happens after stopping the drug. The results describe what happens while people are taking retatrutide. They do not tell us how much weight returns after treatment is stopped.
And it does not mean the drug is available now. Retatrutide remains an investigational drug. Publication in NEJM is a major milestone, but it is not the same thing as regulatory approval.
This is a real milestone. A next-generation obesity drug has now delivered a 25% average weight-loss result in a phase 3 randomized trial and has been formally published in NEJM.
But it is still early in practical terms. The paper supports strong efficacy, not immediate availability.
The most honest summary is simple. Retatrutide looks extremely powerful, but the questions that matter next are head-to-head comparison, long-term safety, access, and what happens after stopping.
This post is a plain-language summary of published research and is not medical advice. Retatrutide is an investigational drug and is not approved for routine clinical use.
Source
Jastreboff AM,
Kaplan LM,
Davies MJ,
et al.,
for the TRIUMPH-1 Investigators.
Retatrutide,
a Triple Hormone Receptor Agonist,
for Treatment of Obesity.
New England Journal of Medicine.
Published September 29, 2026.
doi:10.1056/NEJMoa2604169
ClinicalTrials.gov:
NCT05929066
Comments
Post a Comment